Clinical Trial Update: Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 study of ganetespib plus docetaxel in advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Ganetespib (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2, Phase 3 | Status: TERMINATED